Vertex casually drops Orkambi revenue slowdown, creating
Por um escritor misterioso
Descrição
Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about | Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about the revenue slip, one analyst says.
S-1
Dropbox Stock: Slowing Growth? So What! (NASDAQ:DBX)
S-1
SEC Filing – Royalty Pharma
Comparison of new vs traditional drop system : r/2007scape
Dropbox Business Model - How Dropbox Makes Money?
technologies for profiling single cells to create an open-access
What Investors Need to Know About Oracle's Cloud Slowdown
Oracle Stock (ORCL) Jumps After Revenue Tops Estimates on Strong Cloud Effort - Bloomberg
Vertex to shutter Canada site, focus in on 3 hubs in R&D shuffle
There's A Dark Cloud On Dropbox's Horizon
SEC Filing – Royalty Pharma
424B4
SEC Filing – Royalty Pharma
